The time is now: making the case for compassionate use/pre-approval access to new TB drugs

SUMMARY: Although the majority of people with multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) can now be successfully treated with all-oral shorter regimens, rising rates of resistance to the components in these regimens are a growing global challenge. The drug development pipeline for TB ha...

Descripció completa

Dades bibliogràfiques

Autors principals:	A. Reuter, J. Stillo, S.S. Thi, I. Motta, G.B. Migliori, A. Mesic, M. Mbenga, P. Howell, L. Guglielmetti, A. Gebhard, T. DeCroo, L. D’Ambrosio, J. Furin
Format:	Artigo
Idioma:	Inglês
Publicat:	International Union Against Tuberculosis and Lung Disease (The Union) 2025-12-01
Col·lecció:	IJTLD Open
Matèries:	tuberculosis drug-resistant tb new drugs ethics
Accés en línia:	https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000012/art00002
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!